Description
Created On: 2020-07-15
Record Count: 5
Primary Industries
- Drugs
- Antibody
- Surgical
- Autoimmune
- Disease
- Therapeutic
- Psoriasis
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 279903
Licensor hereby grants to Licensee a co-exclusive (together with Licensor), non-transferable right to Promote and Detail Licensed Products in the Asthma Field in the U.S. Territory, in accordance with applicable law and the Asthma Commercialization Plan.
Licensor Technology means Licensor Know-How and Licensor Patents.
Know-How†means all inventions, discoveries, trade secrets, information, experience, data, formulas, procedures and results related to antibodies that bind to IL-2R, and improvements thereon, including any information regarding the physical, chemical, biological, toxicological, pharmacological, clinical, and veterinary data, dosage regimens, control assays and specifications of Licensed Products.
Licensor Patents means all patent applications owned or Controlled by Licensor or its Affiliates alone or with a Third Party (“Sole Licensor Patentsâ€) and all Joint Licensee-Licensor Patents claiming Licensed Products or their manufacture or use in the Collaborative Fields, which are filed prior to or during the term of this Agreement in the U.S. or any foreign jurisdiction, including any addition, continuation, continuation-in-part or division thereof or any substitute application therefor; any patent issued with respect to such patent application, any reissue, extension or patent term extension of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent; and any other U.S. or foreign patent or inventor’s certificate covering Licensed Products in the Collaborative Fields.
Transplant Indications means all indications that involve the suppression of rejection of transplanted organs, bone marrow or other tissue, including, without limitation, solid organ transplantation (including tolerance induction and xenotransplantation), bone marrow transplantation, graft versus host disease and cell transplantation. In any event, if a given indication satisfies the criteria for both an Autoimmune Indication and a Transplant Indication, such indication shall be deemed a Transplant Indication and not an Autoimmune Indication, provided that an Autoimmune Indication shall not be deemed a Transplant Indication merely because it may cause the need for a transplant (e.g., Type I diabetes, even if it causes the need for an organ transplant).
Asthma Field means the treatment and/or prevention of asthma or other respiratory diseases.
Transplant Field means the Transplant Indications.
IPSCIO Record ID: 279338
Licensor Inventions means all inventions that (a) relate to or are useful with antibodies that bind the IL-2 receptor (IL-2R) and (b) are made during the term of this Agreement by employees of Licensor or persons contractually required to assign or license patent rights covering such inventions to Licensor, in the course of performing Licensor’s obligations, or exercising Licensor’s rights, under this Agreement.
Licensor Patents means all patent applications owned or Controlled by Licensor or its Affiliates (“Sole Licensor Patentsâ€) alone or with a Third Party, and all Joint Licensor-Licensee Patents claiming Licensed Products or their manufacture or use in the Collaborative Fields, which are filed prior to or during the term of this Agreement in the U.S. or any foreign jurisdiction, including any addition, continuation, continuation-in-part or division thereof or any substitute application therefor; any patent issued with respect to such patent application, any reissue, extension or patent term extension of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent; and any other U.S. or foreign patent or inventor’s certificate covering Licensed Products in the Collaborative Fields.
Transplant Field means the Transplant Indications.
A Collaborative Field (i.e., used in the singular) shall refer either to the Asthma Field (unless and until the Asthma Field is excluded from the definition of Collaborative Field) or the Transplant Field (unless and until the Transplant Field is excluded from· the definition of Collaborative Field. Collaborative Fields shall be deemed to exclude the field (i.e., Asthma Field or Transplant Field) with respect to which the rights are so terminated.
IPSCIO Record ID: 275845
Daclizumab shall be deemed to be a Licensed Product, a humanized antibody now known by the generic name daclizumab, which binds to the interleukin-2 receptor (“IL-2Râ€). Daclizumab means any product that contains humanized anti-Tac (as defined under Field).
Licensed Product means any product, other than an Excluded Product, in the Field, including any Combination Product, the making, importation, use, offer for sale, or sale of which utilizes Licensee Know-How, Licensee Patents, or Joint Inventions or would, in the absence of this Second Amended and Restated Worldwide Agreement, infringe a Valid Claim of a Licensee Patent.
Combination Product means any product containing both an ingredient that causes it to be considered a Licensed Product and one or more other therapeutically active ingredients.
Other Licensed Products means all Licensed Products other than Daclizumab.
Licensor Patents means all patent applications owned or Controlled by Licensor alone or with a Third Party (“Sole Licensor Patentsâ€) and all patent applications resulting from Joint Inventions (“Joint Licensee-Licensor Patentsâ€) Covering Daclizumab, which are filed prior to or during the term of the 1989 Agreements, the 1999 Agreements or this Second Amended and Restated Worldwide Agreement in the United States or any foreign jurisdiction, including any addition, continuation, continuation-in-part or division thereof or any substitute application therefor; any patent issued with respect to such patent application, any reissue, extension or patent term extension of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent; and any other United States or foreign patent or inventor’s certificate covering products in the Field.
Licensor Patent Rights:
Patent No. 5,585,089, “Humanized Immunoglobulins,†issued December 17, 1996.
Patent No. 5,693,761, “Polynucleotides Encoding Improved Humanized Immunoglobulins,†issued December 2, 1997.
Patent No. 5,693,762, “Humanized Immunoglobulins,†issued December 2, 1997.
Patent No. 6,180,370 “Humanized Immunoglobulins and Method of Making the Sameâ€, issued January 30, 2001.
Trademarks means the trademark “Zenapax®,†and all trademark registrations and applications therefor, and all goodwill associated therewith, and all other trademarks owned by Licensee (except for any Licensee housemarks or trade names) and used in connection with the sale or promotion of Nutley Dac in the Licensee Territory.
Licensor Know-How means, except as otherwise set forth, all inventions, discoveries, trade secrets, information, experience, data, formulas, procedures and results in the Field, and improvements thereon, including any information regarding the physical, chemical, biological, toxicological, pharmacological, clinical, and veterinary data, dosage regimens, control assays and specifications of Daclizumab.
Licensee Patents means both the Licensee Owned Patents and the Licensee Controlled Patents.
Licensee Owned Patents means all patent applications owned by Licensee or its Affiliates (“Sole Licensee Patentsâ€) alone or with a Third Party, and all patent applications resulting from Joint Inventions (“Joint Licensee-Licensor Patentsâ€) covering inventions in the Field that are filed prior to or during the term of this Second Amended and Restated Worldwide Agreement in the United States or any foreign jurisdiction, including any addition, continuation, continuation-in-part or division thereof or any substitute application therefor; any patent issued with respect to such patent application, any reissue, extension or patent term extension of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent; and any other United States or foreign patent or inventor’s certificate covering inventions in the Field. Licensee Owned Patents as of the Effective Date are, specifically, those listed.
Serial No. 60/416,302 – Use of IL-2 Receptor Antibodies
Joint Inventions means any inventions in the Field, whether patented or not, that are jointly made during the period beginning on January 31, 1989 and continuing until the end of the Commercialization Term by at least one (1) Licensor employee or person contractually required to assign or license patent rights covering such inventions to Licensor and at least one (1) Licensee-Nutley or Licensee employee or person contractually required to assign or license patent rights covering such inventions to Licensee-Nutley or Licensee.
Daclizumab is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis.
IPSCIO Record ID: 279346
Licensor grants a nonexclusive, nontransferable. limited right to use the Licensor trademark.
Compound means the PNP Inhibitor known as –X-4208.
Licensed Product means any and all pharmaceutical products containing Compound.
Autoimmune Indications means all indications that involve pathogenic consequences, including tissue injury, produced by autoantibodies or autoreactive T lymphocytes interacting with self epitopes, i.e., autoantigens.
Transplantation Indications means all indications that involve the suppression of rejection of transplanted organs, bone marrow or other tissue, including, without limitation, solid organ transplantation (including tolerance induction and xenotransplantation), bone marrow transplantation, graft versus host disease and cell transplantation.
BCX-4208 is for the prevention of acute rejection in transplantation and for the treatment of autoimmune diseases.
IPSCIO Record ID: 243659
Licensor grants a worldwide license under the Licensor Patents and Licensor Know-How in the Field to develop, make, have made, use, sell, offer for sale, have sold and import Licensed Products. Such license shall be co-exclusive with Licensor in the Co-Promotion Territory and exclusive even as to Licensor in the Licensee Territory.
Anti-CD11a means that certain monoclonal antibody, and other constructs with minor modifications thereto resulting from changes to the manufacturing process occurring after the transfer thereof from Licensor to Licensee which is now known as Efalizumab, and which recognizes the CD11a cell adhesion molecule on leucocytes, the full length sequences of the light and heavy chains.
'Initial Indications' means the use of Licensed Product for the treatment of psoriasis and the Organ Transplant Indication. For purposes of this Agreement, psoriasis is a single indication regardless of whether the psoriasis is mild, moderate or severe. Separate Initial Indications will not result based on the severity of the psoriasis or organ transplant rejection, the onset period of organ transplant rejection, or the demographics of the patient class.
Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin.
Anti-CD11a is an investigational, recombinant, humanized monoclonal antibody designed to prevent the activation of T-cells and their migration to sites of inflammation. The first Phase III randomized trial will involve approximately 30 sites throughout the United States and Canada for patients with moderate-to-severe plaque psoriasis. A second Phase III study is planned to begin in the first quarter 2000.